<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411358</url>
  </required_header>
  <id_info>
    <org_study_id>FLU11T12A</org_study_id>
    <nct_id>NCT01411358</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects</brief_title>
  <official_title>Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2011-2012, in Non-Elderly Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adimmune Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adimmune Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antibody response to each of the three influenza&#xD;
      vaccine strains included in the licensed seasonal flu vaccine, as measured by&#xD;
      hemagglutination inhibition (HAI) at 21 days post immunization in non-elderly and elderly&#xD;
      subjects in compliance with the requirements of the current European Union (EU)&#xD;
      recommendations for the evaluation of the immunogenicity for a new formulation of a licensed&#xD;
      flu vaccine (CPMP/BWP/214/96).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer ≥ 40.</measure>
    <time_frame>3 weeks post vaccination</time_frame>
    <description>Serum samples will be tested for anti-hemagglutinin (HA) antibodies by hemagglutination inhibition (HAI).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>AdimFlu-S 2011-2012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>non-elderly aged between 18 and 60</intervention_name>
    <description>one dose of 0.5mL AdimFlu-S</description>
    <arm_group_label>AdimFlu-S 2011-2012</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>elderly aged over 60</intervention_name>
    <description>one dose of 0.5mL AdimFlu-S</description>
    <arm_group_label>AdimFlu-S 2011-2012</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or non-pregnant females and aged ≥ 18 years;&#xD;
&#xD;
          -  Willing and able to adhere to visit schedules and all study requirements;&#xD;
&#xD;
          -  Subjects read and signed the study-specific informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject or his/her family is employed by the participated hospital;&#xD;
&#xD;
          -  Subjects received 2010-2011 seasonal influenza vaccine within the previous 6 months;&#xD;
&#xD;
          -  History of hypersensitivity to eggs or egg protein or similar pharmacological effects&#xD;
             to study medication&#xD;
&#xD;
          -  Personal or family history of Guillain-Barré Syndrome&#xD;
&#xD;
          -  An acute febrile illness within 1 week prior to vaccination;&#xD;
&#xD;
          -  Current upper respiratory illness, including the common cold or nasal congestion&#xD;
             within 72 hours&#xD;
&#xD;
          -  Subjects with influenza-like illness as defined by the presence of fever (temperature&#xD;
             ≥ 38°C) and at least two of the following four symptoms: headache, muscle/joint aches&#xD;
             and pains (e.g. myalgia/arthralgia), sore throat and cough&#xD;
&#xD;
          -  Female subjects who are pregnant during the study&#xD;
&#xD;
          -  Treatment with an investigational drug or device, or participation in a clinical&#xD;
             study, within 3 months before consent&#xD;
&#xD;
          -  Immunodeficiency, or under immunosuppressive treatment&#xD;
&#xD;
          -  Receipt of any vaccine within 1 week prior to study vaccination or expected receipt&#xD;
             between Visit 1 (study vaccination) and Visit 2 (final collection of blood samples);&#xD;
&#xD;
          -  Receipt of any blood products, including immunoglobulin in the prior 3 months;&#xD;
&#xD;
          -  Underlying condition in the investigators' opinion may interfere with evaluation of&#xD;
             the vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gin-Hsiang Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

